Edition:
United States

ARIAD Pharmaceuticals Inc (ARIA.O)

ARIA.O on Nasdaq

23.68USD
10:02am EST
Change (% chg)

$-0.00 (-0.02%)
Prev Close
$23.69
Open
$23.67
Day's High
$23.70
Day's Low
$23.67
Volume
3,464,959
Avg. Vol
9,274,724
52-wk High
$23.81
52-wk Low
$4.37

Summary

Name Age Since Current Position

Alexander Denner

46 2016 Independent Chairman of the Board

Paris Panayiotopoulos

42 2016 President, Chief Executive Officer, Director

Manmeet Soni

38 2016 Chief Financial Officer, Executive Vice President, Treasurer

Jennifer Herron

46 2016 Executive Vice President, Chief Commercial Officer

Jayne Gansler

61 2016 Senior Vice President - Human Resources

Daniel Bollag

55 2009 Senior Vice President - Regulatory Affairs and Quality

Maria Cantor

48 2016 Senior Vice President - Corporate Affairs

Hugh Cole

51 2014 Senior Vice President, Chief Business Officer

Timothy Clackson

51 2010 President - Research and Development, Chief Scientific Officer

George Bickerstaff

60 2016 Independent Director

Jules Haimovitz

65 2016 Independent Director

Anna Protopapas

51 2015 Independent Director

Norbert Riedel

58 2011 Independent Director

Sarah Schlesinger

56 2013 Independent Director

Biographies

Name Description

Alexander Denner

Dr. Alexander J. Denner, Ph.D., serves as Independent Chairman of the Board of the Company. He has been a member of our Board since February 2014 and the Chairman of the Board since January 2016. He is the Chief Investment Officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to better provide shareholder value. From 2006 to 2011, Dr. Denner served as a Senior Managing Director of Icahn Capital, an entity through which Carl C. Icahn conducts his investment activities. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm. Dr. Denner has also served as a director of Biogen Inc. since June 2009 and as a director of The Medicines Company since February 2016, both biopharmaceutical companies. Previously, Dr. Denner also served as a director of the following biopharmaceutical companies: Amylin Pharmaceuticals, Inc., Enzon Pharmaceuticals, VIVUS, Inc., and ImClone Systems Incorporated, where he also served as Chairman of the Executive Committee. Dr. Denner was appointed to the Board pursuant to the terms of a nomination and settlement agreement entered into in February 2014, as described in more detail below under the caption “Agreements with Dr. Denner and Sarissa.” Dr. Denner brings to the Board a strong background overseeing the operations and research and development of biopharmaceutical companies and evaluating corporate governance matters. He also has extensive experience as an investor, particularly with respect to healthcare companies and has broad healthcare-industry knowledge. Dr. Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil. and Ph.D. degrees from Yale University.

Paris Panayiotopoulos

Mr. Paris Panayiotopoulos serves as President, Chief Executive Officer, Director of the company., effective January 1, 2016. He has served as our President and Chief Executive Officer and a member of the Board since January 2016. Mr. Panayiotopoulos joined ARIAD from EMD Serono, Inc., a subsidiary of pharmaceutical company Merck KGaA, Darmstadt, Germany, where he served as President from 2013 through 2015. Prior to being appointed President of EMD Serono, Mr. Panayiotopoulos held positions of increasing responsibility within Merck KGaA, serving as President of Merck Serono, Tokyo, Japan, from 2012 through 2013; Global Chief of Staff for the CEO in Geneva, Switzerland, from 2011 through 2012; Head of Western Europe for the fertility and endocrinology franchises, in 2011; Global Director of the neurology franchise, from 2007 through 2011; and Global Strategy and Business Intelligence Director from 2004 through 2007. Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004. Mr. Panayiotopoulos received his combined BSc degree in Chemistry and Management Studies from University College London, and his MSc degree in Marketing and Product Management from Cranfield Business School in the United Kingdom.

Manmeet Soni

Mr. Manmeet S. Soni serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company., effective March 2016. He has served as our Executive Vice President, Chief Financial Officer and Treasurer since March 2016. Previously, he served as chief financial officer of Pharmacyclics, Inc., a biopharmaceutical company, where he was responsible for all finance, procurement, information technology and human resources functions, and played a vital role in Pharmacyclics’ acquisition by AbbVie, Inc. in May 2015. He first joined Pharmacyclics in September 2012 as corporate controller and executive director of finance, and was promoted to vice president, corporate controller in February 2013; senior vice president, finance in August 2013; and executive vice president, finance in November 2013, prior to being appointed as chief financial officer and treasurer in February 2014. Previously, Mr. Soni worked at ZELTIQ Aesthetics Inc., a publicly held medical technology company, from January 2012 to September 2012, where he served as controller, senior director of finance, and was responsible for accounting, SEC and treasury functions. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers in San Jose, CA from June 2007 to January 2012 in the Life Science and Venture Capital Group, providing audit and assurance services to various public and privately held companies in the pharmaceutical, biotechnology, software and semiconductor space. Prior to that, he worked at PricewaterhouseCoopers, India providing audit and assurance services.

Jennifer Herron

Ms. Jennifer Lyn Herron serves as Executive Vice President, Chief Commercial Officer of the Company. Ms. Herron has served as our Executive Vice President, Chief Commercial Officer since May 2016. Ms. Herron joined ARIAD after a ten-year career at Bristol-Myers Squibb Company (BMS), a global pharmaceutical company, where she served most recently as Lead, Commercial Transformation and Operating Model. Previously, Ms. Herron served in various roles of increasing responsibility at BMS, including as Vice President, U.S. Immunology from 2014 to 2016; as General Manager in Puerto Rico and the Caribbean from 2012 to 2014; as Executive Director, U.S. Commercial Operations, from 2010 to 2012; and in several commercial leadership roles in oncology from 2006 through 2009. Prior to joining BMS, Ms. Herron served in marketing roles in oncology for both Novartis and GSK/SmithKline Beecham, and began her pharmaceutical career as a clinical research associate at Boehringer Mannheim Pharmaceuticals. Ms. Herron earned her B.A. in Biology and Economics from Lehigh University and her M.B.A. from Georgetown University.

Jayne Gansler

Ms. Jayne M. Gansler serves as Senior Vice President - Human Resources of the Company. She has served as our Senior Vice President, Human Resources since June 2016. Previously, Ms. Gansler served as Senior Vice President, Global Head of Human Resources for Genzyme, following its acquisition by Sanofi S.A., a global pharmaceutical company, from 2011 to 2015. Prior to that time, Ms. Gansler was Senior Vice President, Global Human Resources for Genzyme Corporation from 2002 until 2011. Prior to joining Genzyme, Ms. Gansler spent over 15 years with Johnson & Johnson Corporation in a variety of senior human resources roles. Ms. Gansler earned her B.A. in Human Resource Management from the University of Massachusetts, Amherst.

Daniel Bollag

Dr. Daniel M. Bollag, Ph.D. serves as Senior Vice President - Regulatory Affairs and Quality of Ariad Pharmaceuticals, Inc. since January 2009. He previously was Vice President, Regulatory Affairs for Genzyme Corporation, a biotechnology company, from 2006 to 2008.

Maria Cantor

Ms. Maria E. Cantor serves as Senior Vice President - Corporate Affairs of Ariad Pharmaceuticals, Inc. since January 2012. She has served as company's Senior Vice President, Corporate Affairs and Human Resources since November 2013, having served as company's Senior Vice President, Corporate Affairs since January 2012. Previously, she served as company's Vice President, Corporate Communications and Investor Relations since July 2008. Ms. Cantor held several positions of increasing responsibility at Genzyme Corporation from 2001 to 2008, most recently serving as Senior Director, Corporate Communications.

Hugh Cole

Mr. Hugh M. Cole serves as Senior Vice President, Chief Business Officer of Ariad Pharmaceuticals, Inc., since March 2014. Previously, from 2007 to 2014, Mr. Cole held management positions at Shire Pharmaceuticals, a biopharmaceutical company, most recently as Senior Vice President, Strategic Planning and Program Management and, previously, as a global franchise head, and before that, as Vice President, Business Development. Previously he held senior positions in business and corporate development at Oscient Pharmaceuticals (formerly, Genome Therapeutics), a pharmaceutical company, and at Millennium Pharmaceuticals, a biopharmaceutical company, and its affiliates. He has an AB degree in chemistry from Harvard and an MBA degree from the Wharton School at the University of Pennsylvania, focused on healthcare management and finance.

Timothy Clackson

Dr. Timothy P. Clackson, Ph.D., serves as President - Research and Development, Chief Scientific Officer of Ariad Pharmaceuticals, Inc. since June 2010. Previously, he served as Senior Vice President and Chief Scientific Officer from September 2003 to June 2010. Dr. Clackson received his B.A. degree in Biochemistry from the University of Oxford, and his Ph.D. degree in Biology from the University of Cambridge for research conducted at the MRC Laboratory of Molecular Biology that included the development of antibody phage display technology.

George Bickerstaff

Mr. George W. Bickerstaff III, serves as Independent Director of the Company. Mr. Bickerstaff has been a member of our Board since April 2016. Mr. Bickerstaff currently serves as a Managing Director of M.M. Dillon & Co., LLC, an investment banking firm, which he joined in 2005. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. From December 1999 to September 2000, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Workscape, Inc., a provider of employee-related information services. From July 1998 to December 1999, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional Services, Inc., a nationwide provider of paper and technology-based document management solutions. From January 1998 to June 1998, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Intellisource Group, Inc., a provider of information technology solutions to the federal, state and local governments and utility markets. From July 1997 to December 1997, Mr. Bickerstaff served as Vice President of Finance of Cognizant Corporation, a global business information services company. From January 1990 to June 1997, Mr. Bickerstaff served in various senior finance roles, including Chief Financial Officer of IMS Healthcare, a global business information services company in the healthcare and pharmaceutical industries. Prior to that, Mr. Bickerstaff held various finance, audit and engineering positions with the Dun & Bradstreet Corporation from 1985 to 1989 and General Electric Company from 1978 to 1985. Mr. Bickerstaff received a Bachelor of Science degree in engineering and a Bachelor of Arts degree in business administration from Rutgers University in 1978.

Jules Haimovitz

Mr. Jules A. Haimovitz serves as Independent Director of the Company. Mr. Haimovitz has been a member of our Board since April 2016. Mr. Haimovitz currently serves as President of the Haimovitz Consulting Group, a private media consulting firm. From July 2002 until July 2007, Mr. Haimovitz served as Vice Chairman and Managing Partner of Dick Clark Productions Inc., a producer of programming for television, cable networks and syndicators. From June 1999 to July 2004, Mr. Haimovitz served in various capacities at Metro Goldwyn Mayer Inc., including President of MGM Networks Inc., a wholly-owned subsidiary. From July 1997 to February 1999, he served as President and Chief Operating Officer of King World Productions, Inc., a worldwide distributor of first-run programming. Mr. Haimovitz has also served in executive positions at Diva Systems Corporation, ITC Entertainment Group, Spelling Entertainment Inc. and Viacom Inc. Mr. Haimovitz previously served on the boards of Blockbuster, Dial Global Inc. (formerly Westwood One), Blucora (formerly Infospace), Orion Pictures Corporation, Lifetime and Video Jukebox Network Inc. Mr. Haimovitz also previously chaired the Audit Committee and the Strategic Planning Committee of ImClone Systems Incorporated through its sale to Eli Lily in 2008. Mr. Haimovitz brings to the Board extensive management, strategic and board experience. Though his experience has been primarily in the media and entertainment industry, Mr. Haimovitz’s experience includes roles as chair of both the audit committee and the strategic planning committee of ImClone Systems through its sale in 2008 to Eli Lilly and Company. Mr. Haimovitz holds a dual Bachelor of Arts degree in mathematics and communications, as well as a Master of Arts degree in mathematics, from Brooklyn College.

Anna Protopapas

Ms. Anna Protopapas serves as Independent Director of ARIAD Pharmaceuticals, Inc. She has been a member of our Board since April 2015. She has been the President and Chief Executive Officer of Mersana Therapeutics, Inc. (“Mersana”), a biotechnology company focused on engineering novel antibody-drug conjugates, since March 2015. From October 2010 to October 2014, she served as a member of the Executive Committee of Takeda Pharmaceutical Company Limited, a global pharmaceutical company, and held various senior management positions, including serving as President of Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda focused in oncology, where she was responsible for leading Takeda’s oncology business, and Executive Vice President of Global Business Development, where she was responsible for global acquisitions, partnering, licensing and venture investing. From October 1997 to October 2010, Ms. Protopapas served in various positions at Millennium Pharmaceuticals, including as the Senior Vice President of Strategy and Business Development and a member of the Executive Committee, where she led the company’s business development initiatives. Ms. Protopapas has been a member of the board of directors of Mersana since March 2015 and was a member of the board of directors of Ensemble Therapeutics, a company focused on engineering novel therapeutics, from 2006 to 2013. engineering practice from Massachusetts Institute of Technology and a MBA from Stanford Graduate School of Business. Ms. Protopapas was appointed to the Board pursuant to the terms of an agreement entered into in April 2015, as described in more detail below under the caption “Agreements with Dr. Denner and Sarissa.” Ms. Protopapas received a B.S. in engineering from Princeton University, an M.S. in chemical engineering practice from Massachusetts Institute of Technology and a MBA from Stanford Graduate School of Business.

Norbert Riedel

Dr. Norbert G. Riedel, Ph.D., serves as Independent Director of Ariad Pharmaceuticals, Inc. He is the President and Chief Executive Officer of Naurex Inc., a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat depression as well as orphan and other challenging diseases of the central nervous system. Before joining Naurex Inc. in January 2014, he was Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company from March 2001 until January 2013. Before assuming this role, from 1998 to 2001, Dr. Riedel served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development at Baxter’s bioscience business. Dr. Riedel was a postdoctoral fellow at Harvard University from 1984 to 1987 and an Assistant Professor and Associate Professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991, is an adjunct professor at Boston University School of Medicine, and an adjunct professor of Medicine at Northwestern University’s Feinberg School of Medicine and was a visiting professor at Massachusetts Institute of Technology in 1992. In 2009, Dr. Riedel was elected as a member of the Austrian Academy of Sciences. Dr. Riedel received his Diploma in biochemistry from the University of Frankfurt in 1981 and his Ph.D. in biochemistry from the University of Frankfurt in 1983.

Sarah Schlesinger

Dr. Sarah J. Schlesinger, M.D., serves as Independent Director of Ariad Pharmaceuticals, Inc., effective July 15, 2013. She has spent more than 20 years working in the field of cellular immunity, including as clinical director of the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. She is currently Senior Attending Physician and Associate Professor of Clinical Investigation at the Laboratory of Molecular Immunology at The Rockefeller University. Before joining The Rockefeller University in 2003, Dr. Schlesinger was a scientist at the International AIDS Vaccine Initiative in New York City from 2002 to 2003. From 1996 to 2002, Dr. Schlesinger was a Research Physician/Pathologist at the Division of Retrovirology at Walter Reed Army Institute of Research, having previously served, from 1994 to 2002, as Staff Pathologist at the Armed Force Institute of Pathology in Washington, DC. Dr. Schlesinger trained in Surgery at the Albert Einstein College of Medicine and began her career in pathology at Georgetown University in Washington, DC, and hospitals in New York including Buffalo General, Hospital New York and the Manhattan Eye, Ear and Throat Hospital. Dr. Schlesinger leads clinical trials and also chairs the research education and training committee of the Center for Clinical and Translational Science at The Rockefeller University Hospital. She is co-director of Rockefeller’s Clinical Scholars program, the Certificate in Clinical and Translational Sciences program and is the vice-chair of the hospital’s Institutional Review Board. Widely published in her field. Dr. Schlesinger received her A.B. degree from Wellesley College in Wellesley, MA, and her M.D. from Rush Medical College in Chicago. She obtained further medical training in Pathology at The New York Hospital—Cornell Medical Center where she was chief resident.